Who is sponsoring NCT05365568?

NCT05365568 is sponsored by AZ Sint-Jan AV.

What drugs are being tested in NCT05365568?

Interventions in NCT05365568: Left Bundle Branch Area Pacing (LBBAP), Biventricular pacing (BiV).

What condition does NCT05365568 study?

NCT05365568 studies Heart Failure with Reduced Ejection Fraction.

Is NCT05365568 still recruiting?

NCT05365568 is currently active, enrolled. Last updated 23 September 2024.

Last reviewed 2024-09-23 · How we verify

NCT05365568: LeCaRT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Left Bundle Branch Area Pacing Using Conventional Stylet-driven Pacemaker Leads for Cardiac Resynchronization Therapy

Active, enrolled NA Last updated 23 September 2024

What this trial tests

NA trial testing Left Bundle Branch Area Pacing (LBBAP) in Heart Failure with Reduced Ejection Fraction in 170 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 September 2022

Primary endpoint
30 September 2025

30 September 2028

Quick facts

Lead sponsor	AZ Sint-Jan AV
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	170
Start date	1 September 2022
Primary completion	30 September 2025
Estimated completion	30 September 2028
Sites	11 locations across Belgium

Drugs / interventions tested

Left Bundle Branch Area Pacing (LBBAP)
Biventricular pacing (BiV)

Conditions studied

Heart Failure with Reduced Ejection Fraction — all drugs for Heart Failure with Reduced Ejection Fraction →

Sponsor

AZ Sint-Jan AV — full company profile →

Who can join

18 and older, any sex, with Heart Failure with Reduced Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study proposal is to compare the effectiveness of two distinct pacing modalities for cardiac resynchronization therapy. Our primary hypothesis is that left bundle branch area pacing (LBBAP) using conventional stylet driven pacemaker leads is an effective resynchronization method that yield to at least similar clinical benefits and outcomes when compare to biventricular pacing.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The Emerging Role of Left Bundle Branch Area Pacing for Cardiac Resynchronisation Therapy.
Diaz JC, Duque M, Aristizabal J, Marin J, et al · · 2023 · cited 18× · PMID 38173800 · DOI 10.15420/aer.2023.15
Left bundle branch pacing set to outshine biventricular pacing for cardiac resynchronization therapy?
Batta A, Hatwal J. · · 2024 · cited 7× · PMID 38690215 · DOI 10.4330/wjc.v16.i4.186
Cardiac Resynchronization Therapy and Conduction System Pacing.
O'Neill TG, Tsushima T, Tayal B. · · 2025 · cited 1× · PMID 40364243 · DOI 10.3390/jcm14093212
Left bundle branch pacing cardiac resynchronization therapy <i>vs</i> biventricular pacing cardiac resynchronization therapy-time to write a requiem for biventricular pacing-cardiac resynchronization therapy.
Pradhan A, Saggu D, Bhandari M. · · 2025 · PMID 40061274 · DOI 10.4330/wjc.v17.i2.103356
Conduction System Pacing for Heart Failure.
Smith NR, Lynch P, Chelu MG. · · 2024 · PMID 39677397 · DOI 10.14503/thij-24-8469

Verify or expand the search:

Other recruiting trials for Heart Failure with Reduced Ejection Fraction

Currently open trials in the same condition.

NCT06826963 — Feasibility and Effectiveness of Eccentric Exercise in Sarcopenic Older Adults with Heart Failure: a Pilot Study · NA · recruiting
NCT06819618 — Prediction of Heart-Failure with Machine Learning · recruiting
NCT06249932 — Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease · Phase 4 · recruiting

Other AZ Sint-Jan AV trials

Trials by the same sponsor.

NCT07501481 — Arrhythmic Risk in Myocarditis Outcome Research · not yet recruiting
NCT04784039 — D-Dimer-based Indication for Transesophageal Echocardiography to Exclude Left Atrial Thrombus Before Cardioversion of No · Phase 4 · unknown
NCT06095765 — Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention · Phase 3 · recruiting
NCT05577078 — TriBEL Registry: National Belgian Registry of Percutaneous Tricuspid Valve Repair Using a Transcatheter Edge-to-edge Rep · not yet recruiting
NCT04640051 — Preprocedural Assessment of Anatomy and Device Sizing With CT and 3D Simulation in Left Atrial Appendage Occlusion. · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05365568 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AZ Sint-Jan AV
Last refreshed: 23 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05365568.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing